Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 3

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 3
---
-Pay” proposal). Our Say-on-Pay proposal received the support of approximately 97% of the votes cast. The Board is appreciative of this support and believes it indicates that stockholders are supportive of our pay program structure and the alignment we have created between management and stockholder interests. A key focus of our ongoing engagement with stockholders in 2024 was to continue the communication with respect to our executive compensation programs. We conducted a robust, Board-driven stockholder outreach and engagement program in the fall of 2024, which informed the Board’s decisions for 2025. We strive to continuously improve our compensation program to drive strong alignment with company performance and with our stockholders’ expectations. See “Stockholder Feedback and Board Responsiveness” on page 51.

We initiated our 2024 stockholder outreach in the fourth quarter to gather input on governance matters, including our executive compensation program. As part of this process, we reached out to stockholders representing 60% of our then-outstanding common stock and held discussions with all who expressed interest. These discussions were led by our Compensation Committee Chair, with participation from certain members of the executive management team, including our CEO and our Vice President of Investor Relations & Corporate Affairs.

#### 2Castle Biosciences 2025 Proxy Statement

#### Proxy Summary
In 2024, our stockholder engagement discussions covered a wide range of topics, including:

• Executive compensation

• Shareholder rights

• Overlapping metrics in short- and long-term incentives

• Desire for CEO pay to align with Company performance and size

• Enhancement to proxy disclosures

• Board structure (classification/super majority vote)

• Artificial intelligence risks

After considering stockholder feedback gathered from previous years and in 2024, as well as input from management and based in part on the Compensation Committee’s independent compensation consultant, the Compensation Committee has continued to approve changes to align our executive compensation program with company growth. These changes over recent years and into 2024 have included:

• Continuing to expand the executive compensation disclosure in our proxy statement to respond to shareholder feedback and better describe the committee process and policy structure;

• Disclosing the material principles underlying Castle’s executive compensation policies and decisions and the most important factors relevant to changes we have made to better align our policies with investor feedback, ongoing trends and good governance practices such as:

◦ Introducing performance-based equity incentive awards in the compensation package in 2022 for our executive officers with the grants to our CEO in 2024 and 2025 consisting of